Page 36 - Read Online

Page 18 of 20 Pellerino et al. J Cancer Metastasis Treat 2020;6:41 I http://dx.doi.org/10.20517/2394-4722.2020.80

to epidermal growth factor receptor-tyrosine kinase inhibitor: comparison between T790M mutation-positive and mutation-negativee
populations. Cancer 2013;119:4325-32.
71. Zhao J, Ye X, Xu Y, Chen MJ, Zhong W, et al. EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant
non-small cell lung cancer with leptomeningeal metastases. Cancer Chemother Pharmacol 2016;78:1305-10.
72. Huang R, Ge M, Zhou X, Ji X, Liao L, et al. Epidermal growth factor receptor mutation detection in cerebrospinal fluid of lung
adenocarcinoma patients with leptomeningeal metastasis. Cancer Biother Radiopharm 2019;34:128-33.
73. Li YS, Jiang BY, Yang JJ, Zhang XC, Zhang Z, et al. Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal
metastases of EGFR-mutant non-small-cell lung: a new medium of liquid biopsy. Ann Oncol 2018;29:945-52.
74. Ma C, Zhang J, Tang D, Ye X, Li J, et al. Tyrosine kinase inhibitors could be effective against non-small-cell lung cancer brain metastases
harboring uncommon EGFR mutations. Front Oncol 2020;10:224.
75. Ma C, Yang X, Xing W, Yu H, Si T, et al. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in
cerebrospinal fluid samples. Thorac Cancer 2020;11:588-93.
76. Nevel KS, DiStefano N, Lin X, Skakodub A, Ogilvie SQ, et al. A retrospective, quantitative assessment of disease burden in patients with
leptomeningeal metastases from non-small-cell lung cancer. Neuro Oncol 2020;22:675-83.
77. Oechsle K, Lange-Brock V, Kruell A, Bokemeyer C, de Wit M. Prognostic factors and treatment options in patients with leptomeningeal
metastases of different primary tumors: a retrospective analysis. J Cancer Res Clin Oncol 2010;136:1729-35.
78. Wolf A, Donahue B, Silverman JS, Chachoua A, Lee J K, et al. Stereotactic radiosurgery for focal leptomeningeal disease in patients with
brain metastases. J Neurooncol 2017;134:139-43.
79. Gani C, Müller AC, Eckert F, Bender B, Pantazis G, et al. Outcome after whole brain radiotherapy alone in intracranial leptomeningeal
carcinomatosis from solid tumors. Strahlenther Onkol 2012;188:148-53.
80. Ozdemir Y, Yildirim BA, Topkan E. Whole brain radiotherapy in management of non-small-cell lung carcinoma associated
leptomeningeal carcinomatosis: evaluation of prognostic factors. J Neurooncol 2016;129:329-35.
81. Brower JV, Saha S, Rosenberg SA, Hullett CR, Robins HI, et al. Management of leptomeningeal metastases: prognostic factors and
associated outcomes. J Clin Neurosci 2016;27:130-7.
82. Hermann B, Hültenschmidt B, Sautter-Bihl ML. Radiotherapy of the neuroaxis for palliative treatment of leptomeningeal carcinomatosis.
Strahlenther Onkol 2001;177:195-9.
83. Devecka M, Duma MN, Wilkens JJ, Kampfer S, Borm KJ, et al. Craniospinal irradiation(CSI) in patients with leptomeningeal metastases:
risk-benefit-profile and development of a prognostic score for decision making in the palliative setting. BMC Cancer 2020;20:501.
84. Yang TJ, Wijetunga NA, Yamada J, Wolden S, Mehallow M, et al. Clinical trial of proton craniospinal irradiation for leptomeningeal
metastases. Neuro Oncol 2020;noaa152.
85. Central Nervous System Cancers: leptomeningeal Metastases (2020). v.2.2020. Available from: http://www.nccn.org. [Last accessed on
21 Oct 2020]
86. Montes de Oca Delgado M, Cacho Díaz B, Santos Zambrano J, Guerrero Juárez V, López Martínez M S, et al. The comparative treatment
of intraventricular chemotherapy by ommaya reservoir vs. lumbar puncture in patients with leptomeningeal carcinomatosis. Front Oncol
2018;8:509.
87. Zairi F, Le Rhun E, Bertrand N, Boulanger T, Taillibert S, et al. Complications related to the use of an intraventricular access device for
the treatment of leptomeningeal metastases from solid tumor: a single centre experience in 112 patients, J Neurooncol 2015;124:317-23.
88. Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, et al. Randomized prospective comparison of intraventricular
methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol
1993;11:561-9.
89. Hitchins RN, Bell DR, Woods RL, Levi JA. A prospective randomized trial of single-agent versus combination chemotherapy in
meningeal carcinomatosis. J Clin Oncol 1987;5:1655-62.
90. Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, et al. A randomized controlled trial comparing intrathecal sustained-
release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res
1999;5:3394-402.
91. Boogerd W, Hart AA, van der Sande JJ, Engelsman E. Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of
treatment. Cancer 1991;67:1685-95.
92. Lin Y, Li H, Huang M, Guo A, Yin Z. Use of ommaya reservoirs to deliver pemetrexed in leptomeningeal metastasis from non-small cell
lung cancer: a case report and review of the literature. Zhongguo Fei Ai Za Zhi 2019;22:546-50.
93. Wu YL, Zhou L, Lu Y. Intrathecal chemotherapy as a treatment for leptomeningeal metastasis of non-small cell lung cancer: a pooled
analysis. Oncol Lett 2016;12:1301-14.
94. Park JH, Kim YJ, Lee JO, Lee KW, Kim JH, et al. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung
cancer in the modern chemotherapy era. Lung Cancer 2012;76:387-92.
95. Ariyasu R, Horiike A, Koyama J, Saiki M, Sonoda T, et al. Efficacy of bevacizumab and erlotinib combination for leptomeningeal
carcinomatosis after failure of erlotinib. Anticancer Drugs 2017;28:565-7.
96. Li Y S, Jiang BY, Yang JJ, Tu HY, Zhou Q, et al. Leptomeningeal metastases in patients with NSCLC with EGFR mutations. J Thorac
Oncol 2016;11:1962-9.
97. Kuiper JL, Hendriks LE, van der Wekken AJ, de Langen AJ, Bahce I, et al. Treatment and survival of patients with EGFR-mutated non-
small-cell cancer and leptomeningeal metastasis: a retrospective cohort analysis. Lung Cancer 2015;89:255-61.
98. Lee E, Keam B, Kim DW, Kim TM, Lee SH, et al. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-